NCT04544995 2026-01-21
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
Phase 1 Terminated
Clinical Trials
13 trialsNCT04456920 2025-12-02
BIO-PSY
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Completed
NCT04233034 2024-11-27
CLVer
Jaeb Center for Health Research
Phase 3 Completed
NCT03027557 2021-05-25
DENOCINA
Aalborg University Hospital
Phase 3 Completed
NCT01976741 2021-05-06
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Bayer
Phase 1 Completed
NCT01865747 2021-04-27
METEOR
Exelixis
Phase 3 Completed
NCT01827930 2020-12-31
MIM
Institut Bergonié
Phase 3 Terminated
NCT00748189 2019-06-25
COMPLEMENT 1
Novartis
Phase 3 Terminated
NCT00703508 2017-06-14
Pharmacogenetics of Metformin Action in PCOS
Virginia Commonwealth University
Phase NA Completed
NCT01943864 2017-05-31
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
GlaxoSmithKline
Phase 2 Completed
NCT00941863 2016-03-22
Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)
Bayer
Phase 1 Completed
NCT01563055 2015-08-10
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed
NCT01808326 2015-06-22
A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Completed